The gastric cancer diagnostic market size has grown strongly in recent years. It will grow from $2.78 billion in 2025 to $2.98 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to limited availability of fluorescent probes, reliance on traditional single-color FISH methods, growing genetic research initiatives, increasing hospital and laboratory infrastructure, adoption of basic cytogenetic diagnostics.
The gastric cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $3.87 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to development of multiplex and high-throughput probes, rising demand for precision medicine, expansion of genetic and pharmaceutical research, technological advancements in imaging and quantification, increasing regulatory compliance and quality standards. Major trends in the forecast period include rising adoption of multiplex and high-throughput fish probes, expansion of genetic and molecular diagnostic applications, growing use in clinical and pharmaceutical research, integration with advanced imaging and analysis technologies, increased focus on probe accuracy and sensitivity.
The rising incidence of gastric cancer is expected to drive growth in the gastric cancer diagnostic market. Gastric cancer, a malignant tumor of the stomach lining, develops when cells grow uncontrollably and can invade surrounding tissues or metastasize. The increase in cases is largely attributed to unhealthy dietary habits, including high consumption of salted, smoked, and processed foods, which damage the stomach lining and elevate cancer risk. Gastric cancer diagnostics facilitate early detection of malignant lesions, enabling timely treatment and improved patient outcomes. They enhance clinical efficiency by providing rapid and accurate results that support better disease management. For example, in May 2024, the American Cancer Society reported 26,890 new stomach cancer cases in the U.S., up from 26,500 in 2023, highlighting the growing need for effective diagnostic solutions.
Companies in this market are innovating with AI-powered endoscopic diagnostic tools to improve early detection and accuracy. AI-based endoscopic diagnostic support devices analyze video images in real time during endoscopy to detect gastrointestinal abnormalities, including early-stage cancer. In March 2024, AI Medical Service Inc., a Japan-based medical technology company, launched GastroAI-model G, which uses deep learning to highlight suspicious lesions on the endoscopic screen, alerting physicians instantly for further examination or biopsy. This innovation improves diagnostic accuracy and enables earlier intervention, which is critical for better patient outcomes.
In April 2025, SSI Diagnostica Group, a Denmark-based microbiology company, acquired Gulf Coast Scientific Corporation, a U.S.-based diagnostics firm specializing in H. pylori testing for gastric cancer risk detection. This acquisition strengthens SSI Diagnostica’s gastrointestinal disease testing capabilities, enhances its presence in the U.S. diagnostics market, and supports growth through innovation and complementary technology in gastric cancer diagnostics.
Major companies operating in the gastric cancer diagnostic market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Qiagen N.V., DiaSorin S.p.A, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Foundation Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Fujirebio Inc., MiRXES Pte Ltd., BIOCEPT Inc., Pillar Biosciences Inc.
North America was the largest region in the gastric cancer diagnostic market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the FISH probe market by raising the cost of imported fluorescent dyes, probe reagents, and advanced manufacturing equipment. Segments such as multiplex and high-throughput probes are particularly affected, with Asia-Pacific regions including China and India experiencing significant import duties. This has led to higher production costs and potential delays in supply. Positively, tariffs are encouraging local manufacturing, innovation in probe synthesis, and investment in domestic production capabilities, enhancing long-term market resilience.
The gastric cancer diagnostic market research report is one of a series of new reports that provides gastric cancer diagnostic market statistics, including gastric cancer diagnostic industry global market size, regional shares, competitors with a gastric cancer diagnostic market share, detailed gastric cancer diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer diagnostic industry. This gastric cancer diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Gastric cancer diagnostics encompass a range of tests and procedures designed to detect and confirm the presence of cancer in the stomach. Their primary objective is to identify gastric tumors at an early stage, determine tumor type and progression, and support effective treatment planning.
The primary types of gastric cancer diagnostics include endoscopy, imaging, biopsy, laboratory tests, and biomarker-based testing. Endoscopy involves inserting a flexible tube equipped with a camera and light to visually examine internal organs and tissues. The products used in these diagnostics include reagents, consumables, and instruments, while the technologies employed range from molecular diagnostics and immunoassays to next-generation sequencing and others. These diagnostics are applied for early detection, screening, and disease monitoring, catering to a wide range of end users such as hospitals, clinics, diagnostic laboratories, and other healthcare facilities.
The gastric cancer diagnostic market consists of revenues earned by entities by providing services such as genetic counselling, risk assessment programmes, telepathology consultations, and patient navigation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer diagnostics market also includes sales of liquid biopsy kits, rapid diagnostic test (RDT) devices, digital pathology scanners, contrast agents for imaging, and lab-on-a-chip systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The gastric cancer diagnostic market size is expected to see strong growth in the next few years. It will grow to $3.87 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to development of multiplex and high-throughput probes, rising demand for precision medicine, expansion of genetic and pharmaceutical research, technological advancements in imaging and quantification, increasing regulatory compliance and quality standards. Major trends in the forecast period include rising adoption of multiplex and high-throughput fish probes, expansion of genetic and molecular diagnostic applications, growing use in clinical and pharmaceutical research, integration with advanced imaging and analysis technologies, increased focus on probe accuracy and sensitivity.
The rising incidence of gastric cancer is expected to drive growth in the gastric cancer diagnostic market. Gastric cancer, a malignant tumor of the stomach lining, develops when cells grow uncontrollably and can invade surrounding tissues or metastasize. The increase in cases is largely attributed to unhealthy dietary habits, including high consumption of salted, smoked, and processed foods, which damage the stomach lining and elevate cancer risk. Gastric cancer diagnostics facilitate early detection of malignant lesions, enabling timely treatment and improved patient outcomes. They enhance clinical efficiency by providing rapid and accurate results that support better disease management. For example, in May 2024, the American Cancer Society reported 26,890 new stomach cancer cases in the U.S., up from 26,500 in 2023, highlighting the growing need for effective diagnostic solutions.
Companies in this market are innovating with AI-powered endoscopic diagnostic tools to improve early detection and accuracy. AI-based endoscopic diagnostic support devices analyze video images in real time during endoscopy to detect gastrointestinal abnormalities, including early-stage cancer. In March 2024, AI Medical Service Inc., a Japan-based medical technology company, launched GastroAI-model G, which uses deep learning to highlight suspicious lesions on the endoscopic screen, alerting physicians instantly for further examination or biopsy. This innovation improves diagnostic accuracy and enables earlier intervention, which is critical for better patient outcomes.
In April 2025, SSI Diagnostica Group, a Denmark-based microbiology company, acquired Gulf Coast Scientific Corporation, a U.S.-based diagnostics firm specializing in H. pylori testing for gastric cancer risk detection. This acquisition strengthens SSI Diagnostica’s gastrointestinal disease testing capabilities, enhances its presence in the U.S. diagnostics market, and supports growth through innovation and complementary technology in gastric cancer diagnostics.
Major companies operating in the gastric cancer diagnostic market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Qiagen N.V., DiaSorin S.p.A, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Foundation Medicine Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Fujirebio Inc., MiRXES Pte Ltd., BIOCEPT Inc., Pillar Biosciences Inc.
North America was the largest region in the gastric cancer diagnostic market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the FISH probe market by raising the cost of imported fluorescent dyes, probe reagents, and advanced manufacturing equipment. Segments such as multiplex and high-throughput probes are particularly affected, with Asia-Pacific regions including China and India experiencing significant import duties. This has led to higher production costs and potential delays in supply. Positively, tariffs are encouraging local manufacturing, innovation in probe synthesis, and investment in domestic production capabilities, enhancing long-term market resilience.
The gastric cancer diagnostic market research report is one of a series of new reports that provides gastric cancer diagnostic market statistics, including gastric cancer diagnostic industry global market size, regional shares, competitors with a gastric cancer diagnostic market share, detailed gastric cancer diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer diagnostic industry. This gastric cancer diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Gastric cancer diagnostics encompass a range of tests and procedures designed to detect and confirm the presence of cancer in the stomach. Their primary objective is to identify gastric tumors at an early stage, determine tumor type and progression, and support effective treatment planning.
The primary types of gastric cancer diagnostics include endoscopy, imaging, biopsy, laboratory tests, and biomarker-based testing. Endoscopy involves inserting a flexible tube equipped with a camera and light to visually examine internal organs and tissues. The products used in these diagnostics include reagents, consumables, and instruments, while the technologies employed range from molecular diagnostics and immunoassays to next-generation sequencing and others. These diagnostics are applied for early detection, screening, and disease monitoring, catering to a wide range of end users such as hospitals, clinics, diagnostic laboratories, and other healthcare facilities.
The gastric cancer diagnostic market consists of revenues earned by entities by providing services such as genetic counselling, risk assessment programmes, telepathology consultations, and patient navigation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer diagnostics market also includes sales of liquid biopsy kits, rapid diagnostic test (RDT) devices, digital pathology scanners, contrast agents for imaging, and lab-on-a-chip systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Gastric Cancer Diagnostic Market Characteristics
3. Gastric Cancer Diagnostic Market Supply Chain Analysis
4. Global Gastric Cancer Diagnostic Market Trends and Strategies
5. Gastric Cancer Diagnostic Market Analysis of End Use Industries
7. Global Gastric Cancer Diagnostic Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Gastric Cancer Diagnostic Total Addressable Market (TAM) Analysis for the Market
9. Gastric Cancer Diagnostic Market Segmentation
10. Gastric Cancer Diagnostic Market Regional and Country Analysis
11. Asia-Pacific Gastric Cancer Diagnostic Market
12. China Gastric Cancer Diagnostic Market
13. India Gastric Cancer Diagnostic Market
14. Japan Gastric Cancer Diagnostic Market
15. Australia Gastric Cancer Diagnostic Market
16. Indonesia Gastric Cancer Diagnostic Market
17. South Korea Gastric Cancer Diagnostic Market
18. Taiwan Gastric Cancer Diagnostic Market
19. South East Asia Gastric Cancer Diagnostic Market
20. Western Europe Gastric Cancer Diagnostic Market
21. UK Gastric Cancer Diagnostic Market
22. Germany Gastric Cancer Diagnostic Market
23. France Gastric Cancer Diagnostic Market
24. Italy Gastric Cancer Diagnostic Market
25. Spain Gastric Cancer Diagnostic Market
26. Eastern Europe Gastric Cancer Diagnostic Market
27. Russia Gastric Cancer Diagnostic Market
28. North America Gastric Cancer Diagnostic Market
29. USA Gastric Cancer Diagnostic Market
30. Canada Gastric Cancer Diagnostic Market
31. South America Gastric Cancer Diagnostic Market
32. Brazil Gastric Cancer Diagnostic Market
33. Middle East Gastric Cancer Diagnostic Market
34. Africa Gastric Cancer Diagnostic Market
36. Gastric Cancer Diagnostic Market Competitive Landscape and Company Profiles
37. Gastric Cancer Diagnostic Market Other Major and Innovative Companies
40. Gastric Cancer Diagnostic Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Gastric Cancer Diagnostic Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses gastric cancer diagnostic market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for gastric cancer diagnostic? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastric cancer diagnostic market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Diagnostic Type: Endoscopy; Imaging; Biopsy; Laboratory Tests; Biomarker-Based Testing2) By Product: Reagents And Consumables; Instruments
3) By Technology: Molecular Diagnostics; Immunoassays; Next-Generation Sequencing; Other Technologies
4) By Application: Early Diagnosis; Screening; Monitoring
5) By End User: Hospitals; Clinics; Diagnostic Laboratories; Other End Users
Subsegments:
1) By Endoscopy: Conventional Endoscopy; Chromoendoscopy; Narrow Band Imaging; Confocal Laser Endomicroscopy; Capsule Endoscopy2) By Imaging: Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Ultrasound
3) By Biopsy: Forceps Biopsy; Needle Biopsy; Endoscopic Ultrasound-Guided Biopsy; Laparoscopic Biopsy
4) By Laboratory Tests: Blood Tests; Stool Tests; Urea Breath Test; Serology
5) By Biomarker-Based Testing: Genetic Testing; Protein Biomarker Testing; Circulating Tumor DNA Testing; Microribonucleic Acid Testing
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Becton Dickinson and Company; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Illumina Inc.; bioMérieux SA; Qiagen N.V.; DiaSorin S.p.A; Natera Inc.; Myriad Genetics Inc.; Fulgent Genetics Inc.; Foundation Medicine Inc.; Invitae Corporation; NeoGenomics Laboratories Inc.; Fujirebio Inc.; MiRXES Pte Ltd.; BIOCEPT Inc.; Pillar Biosciences Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Gastric Cancer Diagnostic market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Becton Dickinson and Company
- Quest Diagnostics Incorporated
- Agilent Technologies Inc.
- Illumina Inc.
- bioMérieux SA
- Qiagen N.V.
- DiaSorin S.p.A
- Natera Inc.
- Myriad Genetics Inc.
- Fulgent Genetics Inc.
- Foundation Medicine Inc.
- Invitae Corporation
- NeoGenomics Laboratories Inc.
- Fujirebio Inc.
- MiRXES Pte Ltd.
- BIOCEPT Inc.
- Pillar Biosciences Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.98 Billion |
| Forecasted Market Value ( USD | $ 3.87 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
